Asynt's Felxible Gas Pressure Reactors
Asynt has announced a range of compact gas pressure reactors designed to be heated and stirred using standard hotplate stirrers with the unique DrySyn adapter that ensures excellent heat transfer.
The base vessels are available from 50 mL to 500 mL and are rated up to 200 Barr and 200 ºC enabling reactions including hydrogenation, carbonylation and carboxylation at elevated temperatures and pressures to be routinely performed.
With the added flexibility of standard and custom DrySyn inserts, Asynt gas pressure reactors provide chemists with a platform to undertake a single reaction from 100s of microlitres, by itself or in parallel, up to a single reaction to the volume of the vessel.
All vessels can be provided with a bursting disc, pressure gauge, pressure relief valve, PT100 temperature probe, thermowell for PT100, cooling coil, magnetic overhead stirrer with standard impeller (316 stainless steel), high pressure burette assembly and a range of glass or PTFE inserts and liners as well as PEEK internals if necessary.
For further information or to discuss your application please contact Asynt on +44 1638 781 709 or [email protected].
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.